BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250318
DTEND;VALUE=DATE:20250321
DTSTAMP:20260515T112538
CREATED:20241107T144640Z
LAST-MODIFIED:20241107T144640Z
UID:40031-1742256000-1742515199@www.pharmajournalist.com
SUMMARY:The 5th Operationalize: Expanded Access Programs Summit
DESCRIPTION:Expanded Access Programs (EAPs) are increasingly recognized as an ethical imperative in modern healthcare. More companies are opening EAPs to provide critical therapies to patients who would otherwise lack access. However\, challenges persist\, especially when navigating the complex regulatory landscape of global programs. From country-specific regulations to post-trial access\, managing global supply chains\, importation\, licensing\, and labeling standards remains a critical focus for ensuring patients worldwide receive the treatments they need. \nJoin over 120 thought leaders from Access\, Medical Affairs\, Clinical Operations\, and Clinical Supply for an unparalleled opportunity to network\, exchange insights\, and explore innovative strategies for overcoming the regulatory and operational hurdles that complicate global access to life-saving therapies. \nAt this year’s summit\, you’ll gain actionable insights on successfully planning and executing Post-Trial Access Programs\, navigating the regulatory landscapes of the US\, LATAM\, Europe\, and South & East Asia\, and developing compliant\, effective global access strategies. You’ll also explore best practices for creating exit plans and transition strategies that address hurdles in reimbursement\, off-request processes\, and country-specific regulations—plus so much more! \nTo know more visit: https://ter.li/org1vd
URL:http://www.pharmajournalist.com/event/the-5th-operationalize-expanded-access-programs-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250318
DTEND;VALUE=DATE:20250321
DTSTAMP:20260515T112538
CREATED:20250127T202012Z
LAST-MODIFIED:20250127T202012Z
UID:40377-1742256000-1742515199@www.pharmajournalist.com
SUMMARY:5th Wet AMD Diabetic Eye Disease Drug Summit
DESCRIPTION:With Merck’s acquisition of EyeBio for $1.3 Billion\, Roche’s Vabysmo launch success and multiple other phase II and III trials in DME\, DR\, RVO\, and Wet AMD\, there is plenty to discuss in the retinal vascular drug space as drug developers seek to new alternatives to anti-VEGF\, explore biosimilars\, and target retinal fibrosis and more to find truly transformative drugs for patients. \n \nThe 2025 Wet AMD & Diabetic Eye Disease Summit is set to be an essential meeting for industry leaders\, research innovators\, and clinical experts dedicated to transforming the landscape of retinal vascular disease treatments. \nWhat’s New for the 2025 Wet AMD & Diabetic Eye Disease Drug Summit? \n\nNew Strategies for Retinal Vascular Drug Clinical Trials: Delve into advanced strategies for designing clinical trials in Wet AMD and diabetic eye disease\, focusing on patient-specific factors and adaptive trial models with insights from Bayer and Aviceda Therapeutics\nEmerging Biomarker Approaches Wet AMD\, DR. DME & RVO: Explore the critical role of biomarkers and clinical endpoints in developing therapies for neovascular retinal disorders\, featuring discussions from Opus Genetics and Ocugen\nInnovative Oral Anti-Inflammatory Treatments for Diabetic Eye Disease: Discover how InflammX Therapeutics is addressing the unmet need in DR and DME patients non-responsive to anti-VEGF therapy with their once-daily oral small molecule\nAdvancements in Retinal Drug Delivery: Discover the benefits of suprachoroidal TKI delivery for Wet AMD with Clearside Biomedical\, and hear from Sanofi about incorporating drug delivery devices to improve physician efficiency and patient compliance\nBreakthroughs in Wet AMD Gene Therapy: Learn about emerging gene therapies for Wet AMD\, focusing on innovative approaches and potential impact on patient care with HuidaGene Therapeutics Doheny Eye Centers\n\nJoin 50+ biopharma experts from clinical\, medical\, regulatory. value and access departments from Bayer\, Sanofi\, EyePoint\, Ocular Therapeutix\, Clearside Biomedical\, RevOpsis\, Opus Genetics\, and HuidaGene Therapeutics as they accelerate towards releasing longer-lasting\, non-invasive and more effective drugs for retinal disease patients. \nTo know more visit: https://ter.li/sew767
URL:http://www.pharmajournalist.com/event/5th-wet-amd-diabetic-eye-disease-drug-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR